Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.77 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.77 |
| ▸ | PI4KA | P42356 | 4/20 | 0.68 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.68 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.68 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.68 |
| ▸ | AHCY | P23526 | 5/20 | 0.66 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8815696 | 0.89 | ADORA2A (0.75) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL25861 | 0.89 | ADORA2A (0.75) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1982410 | 0.87 | ADORA2A (0.73) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL904363 | 0.87 | ADORA2A (1.00) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL29135598 | 0.87 | ADORA2A (0.73) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL17162883 | 0.87 | ADORA2A (0.73) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL5810639 | 0.87 | ADORA2A (1.00) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL17162884 | 0.87 | ADORA2A (0.73) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL29496348 | 0.87 | ADORA2A (1.00) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL29135599 | 0.87 | ADORA2A (0.73) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| WO-2018022221-A1 | PHOSPHORAMIDATE NUCLEOSIDE PRODRUG FOR TREATING VIRAL DISEASES AND CANCER, PROCESSES FOR THEIR PREPARATION AND THEIR USE | ASAVI, LLC (US) | 2018-02-01 | — | — | WO | disclosed |
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-7935726-B1 | Tricyclic pyrones | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | ADORA2A 2591/4885ADORA1 3908/4885PI4KA 12/4885 |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | ADORA2A 2591/4885ADORA1 3908/4885PI4KA 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.